A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial of IFx-Hu2.0 as An Adjunctive Therapy to Pembrolizumab in Checkpoint Inhibitor Naïve Subjects with Advanced or Metastatic Merkel Cell Carcinoma